Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZ-H08905 in Relapsed/Refractory Non-Hodgkin Lymphoma
CTR20254441Phase 2Active
- Sponsor
- Hezheng Pharma
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HZ-H08905 in non-Hodgkin lymphoma (NHL), peripheral T-cell lymphoma (PTCL), natural killer cell lymphoma, T-cell large granular lymphocytic leukemia, natural killer cell leukemia (NKCL), sponsored by Hezheng Pharma. Started Dec 2025; status: active.
02
Drugs
HZ-H08905
03
Conditions
non-Hodgkin lymphoma (NHL)peripheral T-cell lymphoma (PTCL)natural killer cell lymphomaT-cell large granular lymphocytic leukemianatural killer cell leukemia (NKCL)
Beyond the preview
Go deeper on CTR20254441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254441.